Top 10 States for Early-Career Physicians - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Top 10 States for Early-Career Physicians

These 10 states reported physician residency completion totals, physician retention rates, or residency Match fill rates identified in graduate medical education data.

  • By

  • mdspire news news staff

  • June 1, 2026

  • 3 min

Share

Clinical Scorecard: Top 10 States for Early-Career Physicians

At a Glance

CategoryDetail
ConditionPhysician Residency Training and Retention
Key MechanismsResidency training volume, physician retention rates, and Match activity
Target PopulationEarly-career physicians in the United States
Care SettingResidency training programs

Key Highlights

  • California has the highest residency training volume and retention rate at 75.7%.
  • Illinois achieved a 99.7% fill rate in the 2025 Main Residency Match.
  • Massachusetts and Wisconsin both reported fill rates of 99.8% in their residency programs.
  • Michigan had a 99.9% fill rate, with 45 more positions offered than in 2024.
  • Ohio and New Jersey offered more positions in 2025 compared to the previous year.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not applicable

          Not applicable

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Top 10 States for Early-Career Physicians

            • by mdspire news news staff

            • June 1, 2026

            Related Content

            Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

            Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

            ADHD Stimulant Misuse Under Review

            High-frequency misuse remains associated with polysubstance use, while no studies evaluated long-term physical health outcomes.

            FDA Approves First Oral PCSK9 Inhibitor

            Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.